Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (13) 13
science & technology (13) 13
female (11) 11
humans (11) 11
oncology (10) 10
aged (9) 9
middle aged (9) 9
adult (6) 6
hematology, oncology and palliative medicine (6) 6
ovarian cancer (6) 6
disease-free survival (5) 5
ovarian neoplasms - drug therapy (5) 5
tumors (5) 5
aged, 80 and over (4) 4
cancer (4) 4
clinical trials (4) 4
neoplasm recurrence, local - drug therapy (4) 4
analysis (3) 3
breast cancer (3) 3
cancer therapies (3) 3
care and treatment (3) 3
chemotherapy (3) 3
diseases (3) 3
double-blind method (3) 3
medical colleges (3) 3
obstetrics & gynecology (3) 3
prognosis (3) 3
relapse (3) 3
retrospective studies (3) 3
survival analysis (3) 3
womens health (3) 3
young adult (3) 3
abdomen (2) 2
abridged index medicus (2) 2
anemia - chemically induced (2) 2
angiogenesis (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
deoxyribonucleic acid--dna (2) 2
general & internal medicine (2) 2
gynecology (2) 2
health risk assessment (2) 2
hospitals (2) 2
lymphatic metastasis (2) 2
maintenance chemotherapy (2) 2
medical research (2) 2
medicine & public health (2) 2
medicine, general & internal (2) 2
metastasis (2) 2
multivariate analysis (2) 2
mutation (2) 2
neoplasm staging (2) 2
oncology, experimental (2) 2
ovarian neoplasms - mortality (2) 2
ovarian neoplasms - pathology (2) 2
ovarian neoplasms - surgery (2) 2
paclitaxel - administration & dosage (2) 2
patient outcomes (2) 2
phthalazines - adverse effects (2) 2
phthalazines - therapeutic use (2) 2
piperazines - adverse effects (2) 2
piperazines - therapeutic use (2) 2
proportional hazards models (2) 2
research (2) 2
surgery (2) 2
abdominal pain - chemically induced (1) 1
abnormalities (1) 1
adjuvant treatment (1) 1
adolescent (1) 1
age (1) 1
aging - physiology (1) 1
anemia (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiopoietin-1 - antagonists & inhibitors (1) 1
angiopoietin-2 - antagonists & inhibitors (1) 1
antibodies, bispecific - administration & dosage (1) 1
antibodies, bispecific - adverse effects (1) 1
antibodies, bispecific - therapeutic use (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
ascites (1) 1
ascites - drug therapy (1) 1
ascites - mortality (1) 1
ascites - pathology (1) 1
biological and medical sciences (1) 1
biological evolution (1) 1
biomarkers, tumor - analysis (1) 1
blood pressure (1) 1
brca1 protein (1) 1
brca1 protein - genetics (1) 1
brca2 protein (1) 1
brca2 protein - genetics (1) 1
breast neoplasms - diagnostic imaging (1) 1
breast neoplasms - genetics (1) 1
breast neoplasms - pathology (1) 1
breast neoplasms - physiopathology (1) 1
cancer and oncology (1) 1
cancer och onkologi (1) 1
carboplatin (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
by Ledermann, Jonathan A, Prof and Harter, Philipp, MD and Gourley, Charlie, Prof and Friedlander, Michael, Prof and Vergote, Ignace, Prof and Rustin, Gordon, Prof and Scott, Clare, PhD and Meier, Werner, Prof and Shapira-Frommer, Ronnie, MD and Safra, Tamar, MD and Matei, Daniela, MD and Fielding, Anitra, MBChB and Spencer, Stuart, MSc and Rowe, Philip, MSc and Lowe, Elizabeth, MD and Hodgson, Darren, PhD and Sovak, Mika A, MD and Matulonis, Ursula, MD
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1579 - 1589
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Double-Blind Method | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - drug therapy | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | Phthalazines - therapeutic use | Aged, 80 and over | Cystadenocarcinoma, Serous - mortality | Adult | Female | Aged | Mutation | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Phthalazines - adverse effects | Medical colleges | Care and treatment | Relapse | Hospitals | Gene mutations | Analysis | Patient outcomes | Clinical trials | Ovarian cancer | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
by Ledermann, Jonathan, Prof and Harter, Philipp, MD and Gourley, Charlie, Prof and Friedlander, Michael, Prof and Vergote, Ignace, Prof and Rustin, Gordon, Prof and Scott, Clare L, PhD and Meier, Werner, Prof and Shapira-Frommer, Ronnie, MD and Safra, Tamar, MD and Matei, Daniela, MD and Fielding, Anitra, MBChB and Spencer, Stuart, MSc and Dougherty, Brian, PhD and Orr, Maria, PhD and Hodgson, Darren, PhD and Barrett, J Carl, PhD and Matulonis, Ursula, MD
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 852 - 861
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Neoplasms, Cystic, Mucinous, and Serous - genetics | Ovarian Neoplasms - genetics | Antineoplastic Agents - adverse effects | Genes, BRCA2 | Germ-Line Mutation | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Maintenance Chemotherapy | Retrospective Studies | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Proportional Hazards Models | Anemia - chemically induced | Piperazines - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Disease-Free Survival | Phthalazines - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Phthalazines - adverse effects | Medical colleges | Care and treatment | Relapse | Analysis | Patient outcomes | Ovarian cancer | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Clinical management of uterine sarcomas
by Amant, Frédéric, Prof and Coosemans, An, MD and Debiec-Rychter, Maria, Prof and Timmerman, Dirk, Prof and Vergote, Ignace, Prof
The lancet oncology, ISSN 1470-2045, 2009, Volume 10, Issue 12, pp. 1188 - 1198
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Sarcoma, Endometrial Stromal - drug therapy | Sarcoma, Endometrial Stromal - pathology | Leiomyosarcoma - pathology | Uterine Neoplasms - pathology | Humans | Uterine Neoplasms - drug therapy | Female | Leiomyosarcoma - drug therapy | Sarcoma - diagnosis | Uterine Neoplasms - diagnosis | Sarcoma - drug therapy | Sarcoma - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
by du Bois, Andreas, Prof and Kristensen, Gunnar, Prof and Ray-Coquard, Isabelle, Prof and Reuss, Alexander, MSc and Pignata, Sandro, MD and Colombo, Nicoletta, Prof and Denison, Ursula, MD and Vergote, Ignace, Prof and del Campo, Jose M, MD and Ottevanger, Petronella, PhD and Heubner, Martin, MD and Minarik, Thomas, PhD and Sevin, Emmanuel, MD and de Gregorio, Nikolaus, MD and Bidziński, Mariusz, Prof and Pfisterer, Jacobus, Prof and Malander, Susanne, MD and Hilpert, Felix, Prof and Mirza, Mansoor R, MD and Scambia, Giovanni, Prof and Meier, Werner, Prof and Nicoletto, Maria O, MD and Bjørge, Line, Prof and Lortholary, Alain, MD and Sailer, Martin Oliver, PhD and Merger, Michael, MD and Harter, Philipp, MD and AGO Study Group led Gynecologic Cancer Intergroup (GCIG)/European Network of Gynaecologic Oncology Trials Groups (ENGOT) Intergroup Consortium and European Network Gynaecologic Onco and AGO Study Grp Led Gynecologic Canc and AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Epithelial ovarian cancer
by Lheureux, Stephanie and Gourley, Charlie and Vergote, Ignace and Oza, Amit M
The Lancet (British edition), ISSN 0140-6736, 03/2019, Volume 393, Issue 10177, pp. 1240 - 1253
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Medical research | International cooperation | Analysis | Genomics | Adjuvant treatment | Medicine, Experimental | Disease susceptibility | Health aspects | Ovarian cancer | Cancer | Therapy | Ovarian carcinoma | Biological evolution | DNA damage | Homologous recombination | Clinical trials | Homology | Subgroups | Surgery | Deoxyribonucleic acid--DNA | BRCA2 protein | Sensitivity analysis | BRCA1 protein | Breast cancer | Disease control | Patients | Abdomen | Quality of life | Womens health | Mutation | Health risk assessment | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
by Monk, Bradley J, Prof and Poveda, Andrés, MD and Vergote, Ignace, MD and Raspagliesi, Francesco, MD and Fujiwara, Keiichi, MD and Bae, Duk-Soo, MD and Oaknin, Ana, MD and Ray-Coquard, Isabelle, MD and Provencher, Diane M, MD and Karlan, Beth Y, MD and Lhommé, Catherine, MD and Richardson, Gary, MD and Rincón, Dolores Gallardo, MD and Coleman, Robert L, MD and Herzog, Thomas J, MD and Marth, Christian, PhD and Brize, Arija, MD and Fabbro, Michel, MD and Redondo, Andrés, MD and Bamias, Aristotelis, PhD and Tassoudji, Marjan, MS and Navale, Lynn, MS and Warner, Douglas J, MD and Oza, Amit M, MD
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 799 - 808
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Double-Blind Method | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Withholding Treatment | Angiopoietin-1 - antagonists & inhibitors | Disease-Free Survival | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Female | Aged | Edema - chemically induced | Angiopoietin-2 - antagonists & inhibitors | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Recombinant Fusion Proteins - administration & dosage | Clinical trials | Medical colleges | Relapse | Diseases | Ovarian cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study
by Oonk, Maaike H, MD and van Hemel, Bettien M, MD and Hollema, Harry, Prof and de Hullu, Joanne A, PhD and Ansink, Anca C, PhD and Vergote, Ignace, Prof and Verheijen, René H, Prof and Maggioni, Angelo, MD and Gaarenstroom, Katja N, PhD and Baldwin, Peter J, PhD and van Dorst, Eleonora B, MD and van der Velden, Jacobus, PhD and Hermans, Ralph H, PhD and van der Putten, Hans W, PhD and Drouin, Pierre, MD and Runnebaum, Ingo B, PhD and Sluiter, Wim J, PhD and van der Zee, Ate G, Prof
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 7, pp. 646 - 652
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Vulvar Neoplasms - surgery | Prognosis | Neoplasm Recurrence, Local - prevention & control | Humans | Proportional Hazards Models | Lymphatic Metastasis | Secondary Prevention | Disease-Free Survival | Vulvar Neoplasms - pathology | Groin | Survival Analysis | Female | Aged | Sentinel Lymph Node Biopsy | Research | Metastasis | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)
by Rohr, Irena and Alavi, Sara and Richter, Rolf and Keller, Maren and Chekerov, Radoslav and Oskay-Özcelik, Gülten and Heinrich, Michaela and Taskiran, Cagatay and Joly, Florence and Berger, Regina and du Bois, Andreas and Gornjec, Andreja and Vergote, Ignace and Achimas-Cadariu, Patriciu and Lorusso, Domenica and Maenpaa, Johanna and Sehouli, Jalid
International journal of gynecological cancer, ISSN 1048-891X, 04/2020, Volume 30, Issue 4, pp. 509 - 514
Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Decision Making | Ovarian Neoplasms - psychology | Europe | Humans | Middle Aged | Patient Preference - statistics & numerical data | Neoplasm Recurrence, Local - drug therapy | Young Adult | Adolescent | Aged, 80 and over | Adult | Female | Surveys and Questionnaires | Aged | Maintenance Chemotherapy | Neoplasm Recurrence, Local - psychology | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Patient Preference - psychology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights